## SDHA Antibody Cell Signaling 0rders: 877-616-CELL (2355)<br/>orders@cellsignal.com Support: 877-678-TECH (8324) Web: info@cellsignal.com<br/>cellsignal.com<br/>cellsignal.com 3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IF-IC	<b>Reactivity:</b> H M R Mk	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 70	<b>Source/Isotype:</b> Rabbit	<b>UniProt ID:</b> #P31040	Entrez-Gene Id: 6389
Product Usage Information	e	<b>Application</b> Western Blotting Immunofluorescence	(Immunocytochem	iistry)		<b>Dilution</b> 1:1000 1:50
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		SDHA Antibody recognizes endogenous levels of total SDHA protein.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human SDHA protein. Antibodies are purified by protein A and peptide affinity chromatography.				
Background		Succinate dehydrogenase (SDH), also known as Complex II or succinate:quinone oxidoreductase, is a key component of the citric acid cycle and the electron transport chain (1). Specifically, it is involved in the oxidation of succinate (2). SDH consists of four subunits: SDHA, SDHB, SDHC, and SDHD (3). Research studies have shown that defects in SDHA cause complex II deficiency (2). In addition, investigators have observed reduction of SDHA in the striatum of patients with Huntington's disease (3), and reduction of SDHB, SDHC, and SDHD in paragangliomas and phenochromocytomas (4,5).				
Background References		1. Oyedotun, K.S. and Lemire, B.D. (2004) <i>J Biol Chem</i> 279, 9424-31. 2. Bourgeron, T. et al. (1995) <i>Nat Genet</i> 11, 144-9. 3. Benchoua, A. et al. (2006) <i>Mol Biol Cell</i> 17, 1652-63. 4. Baysal, B.E. et al. (2000) <i>Science</i> 287, 848-51. 5. Feichtinger, R.G. et al. (2010) <i>BMC Cancer</i> 10, 149.				
Species Reactivity		Species reactivity is determined by testing in at least one approved application (e.g., western blot).				
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
Applications Key		W: Western Blotting IF-IC: Immunofluorescence (Immunocytochemistry)				
Cross-Reactivity Key		H: Human M: Mouse R: Rat Mk: Monkey				
Trademarks and Patents		Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.				
		All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.				
Limited Uses		Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CS the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of n force or effect.				
		approved, cleared, or purpose. Customer sl any manner that conf Customer as the end- diagnostic, prophylac	licensed by the FDA nall not use any Pro licts with its labelin user and solely for tic or therapeutic pr	lse Only or a similar labe A or other regulatory for duct for any diagnostic of g statement. Products so research and developme urposes, or any purchaso e, requires a separate lio	eign or domestic en or therapeutic purp old or licensed by C ent uses. Any use o e of Product for res	ntity, for any ose, or otherwise in ST are provided for f Product for ale (alone or as a

sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.